Trial Search Results

Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes

This is a multi-center, Phase II, cross-sectional study comparing quality of life (QOL) as assessed by patient-reported outcomes (PROs) in older (≥65 years) adults vs younger (55-64 years) undergoing allogeneic hematopoietic cell transplantation (HCT) for myelodysplastic syndromes (MDS).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Center for International Blood and Marrow Transplant Research

Collaborator: Medical College of Wisconsin

Stanford Investigator(s):


  • Behavioral: ePRO survey


Inclusion Criteria:

In order to be eligible to participate on this study, an individual must meet all of the
following criteria:

   1. Underwent an allogeneic HCT for MDS on the 10-CMSMDS-1 protocol

   2. Prior consent to research and future contact by the CIBMTR

   3. Ability to provide RCI BMT protocol 17-ePRO signed and dated informed consent form

   4. Age ≥55 years at time of transplant

   5. Fluent in English or Spanish

   6. Greater than 6 months post-HCT

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation
on this study.

   1. No access to an internet browser or email account

   2. Within 6 months of first HCT for MDS on the 10-CMSMDS-1 protocol

Ages Eligible for Study

55 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Michelle Chin, MS
Not Recruiting